<DOC>
	<DOCNO>NCT00375648</DOCNO>
	<brief_summary>This study evaluate efficacy safety 4 mg zoledronic acid administer intravenously every 3-4 week treatment bone metastases-related pain patient prostate cancer .</brief_summary>
	<brief_title>Efficacy Safety Zoledronic Acid Treatment Bone Metastases-related Pain Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Histologically proven adenocarcinoma prostate Bonescan document metastasis Age &gt; 18 year Noncontrolled bone pain despite systemic antitumor therapy ( hormone chemotherapy ) initiate least 4 week inclusion Life expectancy &gt; 3 month Written inform consent New systemic antitumor therapy initiate less 4 week study entry predictable need start new treatment within 8 week Radiation therapy bone target lesion bonetargeted isotope therapy ( strontium samarium ) complete less 4 week study entry Bisphosphonate therapy within 8 week study entry Abnormal renal function ( serum creatinine &gt; 2 x upper normal limit creatinine clearance &lt; 30 ml/min ) Corrected serum calcium &gt; 3 mmol/L &lt; 2 mmol/L Clinically relevant hypersensitivity zoledronic acid , another bisphosphonate , one component present formulation study drug Severe concomitant medical condition could hamper patient 's quality life influence interpretation pain Patients unable fill questionnaire ( neurologic psychiatric condition , illiteracy , etc . ) Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Bone metastases-related pain</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>